<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084626</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1 antibody-EBV</org_study_id>
    <nct_id>NCT04084626</nct_id>
  </id_info>
  <brief_title>PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV</brief_title>
  <official_title>A Clinical Trial of Programmed Cell Death Protein 1(PD1) Antibody and Lenalidomide as a Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis or Chronic Active EBV Infection(CAEBV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active
      EBV infection patients were selected as the main subjects to evaluate the effect of PD-1
      antibody and lenalidomide regimens on ebv-dna and safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Epstein-Barr virus(EBV)-DNA</measure>
    <time_frame>6 months</time_frame>
    <description>PBMC and plasma EBV-DNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The spleen size</measure>
    <time_frame>6 months</time_frame>
    <description>Ultrasonic spleen size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>through study completion, an average of 1 years</time_frame>
    <description>Adverse events including thyroid function， liver function damage, myelosuppression, infection, bleeding and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>1 year</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>EBV Infection</condition>
  <arm_group>
    <arm_group_label>PD-1 antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 antibody and lenalidomide administered in 2 week cycles for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD1 antibody</intervention_name>
    <description>2mg/kg ivgtt on day 1(age&lt;18 years); 200mg ivgtt on day 1(age &gt;=18 years).</description>
    <arm_group_label>PD-1 antibody</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>5mg orally once a day（age&lt;18years) ,day 1-14; 10mg orally once a day(age&gt;=18years), day 1-14.</description>
    <arm_group_label>PD-1 antibody</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients were older than 1 years of age.

          2. According to the HLH-04 diagnostic criteria, it meets the HLH diagnostic criteria. EBV
             infection occurs in cells with EBV-DNA copy number significantly increased in
             peripheral blood or tissue, or where EBV coding small RNA(EBER) is detected in tissue
             or peripheral blood. Or Straus' 1988 diagnostic criteria for CAEBV.

          3. EBV-HLH or CAEBV are in remission.

          4. Informed consent

        Exclusion Criteria:

          1. Heart function above grade II (NYHA).

          2. Pregnancy or lactating Women.

          3. Allergic to PD-1 antibody or lenalidomide.

          4. Active bleeding of the internal organs.

          5. uncontrollable infection.

          6. Participate in other clinical research at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jingshi wang</last_name>
    <phone>86-010-63139862</phone>
    <email>wangjingshi987@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jingshi wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 8, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>February 8, 2020</last_update_submitted>
  <last_update_submitted_qc>February 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

